NO982275D0 - FremgangsmÕter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF) - Google Patents

FremgangsmÕter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)

Info

Publication number
NO982275D0
NO982275D0 NO982275A NO982275A NO982275D0 NO 982275 D0 NO982275 D0 NO 982275D0 NO 982275 A NO982275 A NO 982275A NO 982275 A NO982275 A NO 982275A NO 982275 D0 NO982275 D0 NO 982275D0
Authority
NO
Norway
Prior art keywords
methods
treating
gdnf
cell line
retinopathies
Prior art date
Application number
NO982275A
Other languages
English (en)
Other versions
NO982275L (no
Inventor
Jean-Claude Marcel Louis
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO982275D0 publication Critical patent/NO982275D0/no
Publication of NO982275L publication Critical patent/NO982275L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Non-Volatile Memory (AREA)
NO982275A 1995-11-29 1998-05-19 Fremgangsmöter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF) NO982275L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/564,833 US5641750A (en) 1995-11-29 1995-11-29 Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
PCT/US1996/018806 WO1997019694A1 (en) 1995-11-29 1996-11-22 Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product

Publications (2)

Publication Number Publication Date
NO982275D0 true NO982275D0 (no) 1998-05-19
NO982275L NO982275L (no) 1998-07-29

Family

ID=24256084

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982275A NO982275L (no) 1995-11-29 1998-05-19 Fremgangsmöter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)

Country Status (20)

Country Link
US (2) US5641750A (no)
EP (1) EP0863766B1 (no)
JP (1) JP2000502057A (no)
KR (1) KR19990071540A (no)
CN (1) CN1203532A (no)
AT (1) ATE194773T1 (no)
AU (1) AU698062B2 (no)
BR (1) BR9611750A (no)
CZ (1) CZ154498A3 (no)
DE (1) DE69609422T2 (no)
DK (1) DK0863766T3 (no)
ES (1) ES2149511T3 (no)
GR (1) GR3034393T3 (no)
HU (1) HUP9802374A2 (no)
IL (1) IL124601A0 (no)
MX (1) MX9803993A (no)
NO (1) NO982275L (no)
PT (1) PT863766E (no)
SK (1) SK65998A3 (no)
WO (1) WO1997019694A1 (no)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064870A1 (en) * 1993-03-03 2002-05-30 Pascale Briand Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2710846B1 (fr) 1993-10-04 1995-12-22 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
US8431119B2 (en) * 1993-10-04 2013-04-30 Aventis Pharma S.A. Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
EP0751992B1 (en) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6878544B2 (en) * 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
CA2265743A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic composition of neurotrophic factor, optic nerve functional disorder-treating agent and method for treating optic nerve functional disorder
EP0937258A2 (en) * 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
AU748639B2 (en) * 1997-04-17 2002-06-06 Washington University Receptors for TGF-beta-related neurotrophic factors
US20030121064A1 (en) * 1997-06-11 2003-06-26 Ann Logan CNS neuroregenerative compositions and methods of use
CA2301693A1 (en) * 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
US6906077B1 (en) * 1998-12-03 2005-06-14 Alcon Manufacturing, Ltd. Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
EP1985632A3 (en) * 1999-02-08 2008-11-12 Human Genome Sciences, Inc. Use of VEGF2 antibodies for inhibiting photoreceptor cell proliferation
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
EP1279406A4 (en) 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
WO2002011769A1 (en) 2000-08-04 2002-02-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CZ2003444A3 (cs) * 2000-08-08 2003-10-15 M. G. V. S. Ltd. Konstrukty nukleové kyseliny, vaskulární buňky jimi transformované a farmaceutické prostředky a způsoby používající je k indukci angiogenesy
CN100411686C (zh) * 2001-04-11 2008-08-20 千寿制药株式会社 视觉功能障碍改善剂
EP1385864B1 (en) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 antibodies
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
WO2003028765A1 (fr) * 2001-09-28 2003-04-10 Santen Pharmaceutical Co., Ltd. Injections pour tissu oculaire contenant un medicament lie a du polyethylene glycol
US20030129164A1 (en) * 2001-12-03 2003-07-10 Flannery John G. Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
AU2002359786A1 (en) * 2001-12-19 2003-07-09 Hiroaki Mizukami Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
WO2003061519A2 (en) * 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
EP1551956A4 (en) * 2002-07-12 2006-12-27 Univ Washington METHOD AND SYSTEMS FOR THE EXTENDED IN VITRO CULTURE OF NEURONAL CELLS
JP2006507368A (ja) * 2002-09-29 2006-03-02 サーモディックス，インコーポレイティド ステロイド含有治療剤の網膜下投与方法；脈絡膜及び網膜に薬力学作用を局在化するための方法；並びに網膜疾患の治療及び／又は予防のための関連する方法
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US20060223177A1 (en) 2003-06-27 2006-10-05 Ethicon Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
EP2336298B1 (en) 2003-06-27 2016-02-17 DePuy Synthes Products, Inc. Postpartum cells derived from placental tissue and methods of making and using the same
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
GB0328021D0 (en) 2003-12-03 2004-01-07 Inst Of Ophthalmology Method
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
WO2006083394A2 (en) * 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20060171930A1 (en) * 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
DK1835924T3 (da) 2004-12-23 2013-11-04 Ethicon Inc Behandling af parkinsons sygdom og beslægtede sygdomme under anvendelse af postpartum opnåede celler
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US8409263B2 (en) * 2005-08-05 2013-04-02 Gholam A. Peyman Methods to regulate polarization of excitable cells
WO2007019427A2 (en) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
WO2007070870A1 (en) * 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
ES2628129T3 (es) * 2005-12-28 2017-08-01 DePuy Synthes Products, Inc. Tratamiento de la enfermedad vascular periférica utilizando células derivadas del posparto
US20080145405A1 (en) * 2006-12-15 2008-06-19 Kunzler Jay F Drug delivery devices
EP2076124A4 (en) * 2007-04-20 2011-08-03 Acucela Inc STYRENYL DERIVATIVE COMPOUNDS FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASES AND SUFFERING
US8299307B2 (en) 2007-06-29 2012-10-30 Acucela Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
MX337100B (es) 2007-10-05 2016-02-11 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
WO2009046335A1 (en) * 2007-10-05 2009-04-09 Ethicon, Incorporated Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
JP5518893B2 (ja) 2008-12-19 2014-06-11 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 肺ならびに肺の疾患および障害の治療
BRPI0923177A2 (pt) * 2008-12-19 2020-08-25 Advanced Technologies And Regenerative Medicine, Llc usos de composições para tratar dor neuropática e espacidade, as referidas composições, e kit
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
EP2379089B1 (en) * 2008-12-19 2019-04-17 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue following injury
PL2411504T3 (pl) 2009-03-26 2017-10-31 Depuy Synthes Products Inc Komórki ludzkiej tkanki pępowinowej jako terapia choroby Alzheimera
MX362198B (es) 2011-12-23 2019-01-08 Depuy Synthes Products Llc Deteccion de celulas derivadas de tejido de cordon umbilical humano.
CN104703598A (zh) 2012-01-20 2015-06-10 奥克塞拉有限公司 用于疾病治疗的取代的杂环化合物
MX2015012435A (es) 2013-03-12 2016-01-25 Acucela Inc Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
AU2017357931A1 (en) 2016-11-10 2019-06-20 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
US11229662B2 (en) 2016-11-15 2022-01-25 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
WO2019070917A1 (en) 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
EP3710008A4 (en) 2017-11-14 2021-08-25 The Schepens Eye Research Institute, Inc. RUNX1 INHIBITION FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND DISEASES ASSOCIATED WITH EPITHELIAL-MESENCHYMAL TRANSITION
CN113759131B (zh) * 2021-09-28 2024-10-29 嘉兴蔚康科技有限公司 一种靶标蛋白组合在检测视网膜黄斑病变中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3995635A (en) * 1971-09-09 1976-12-07 Alza Corporation Ocular insert
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4217898A (en) * 1978-10-23 1980-08-19 Alza Corporation System with microporous reservoir having surface for diffusional delivery of agent
US4474452A (en) * 1981-05-13 1984-10-02 Pitney Bowes Inc. Safety device for cam yoke used in electrophotocopier reciprocating carriage
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4882150A (en) * 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
EP1241258A3 (en) * 1989-10-16 2003-12-10 Amgen Inc. Stem cell factor
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
HU220795B1 (hu) * 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
JP3645902B2 (ja) * 1992-02-14 2005-05-11 リジェネロン ファーマシューティカルズ，インコーポレーテッド 特定の因子による網膜の損傷および変性の防止
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
WO1993021902A1 (en) * 1992-04-24 1993-11-11 Somatix Therapy Corporation Biocompatible, therapeutic, implantable device
WO1995017203A1 (en) * 1993-12-22 1995-06-29 The University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
AU1059297A (en) 1997-06-19
HUP9802374A2 (hu) 1999-02-01
DK0863766T3 (da) 2000-10-23
IL124601A0 (en) 1998-12-06
GR3034393T3 (en) 2000-12-29
BR9611750A (pt) 1999-04-06
CZ154498A3 (cs) 1999-05-12
EP0863766A1 (en) 1998-09-16
ATE194773T1 (de) 2000-08-15
WO1997019694A1 (en) 1997-06-05
KR19990071540A (ko) 1999-09-27
ES2149511T3 (es) 2000-11-01
DE69609422D1 (de) 2000-08-24
SK65998A3 (en) 1999-09-10
US5736516A (en) 1998-04-07
CN1203532A (zh) 1998-12-30
DE69609422T2 (de) 2001-02-15
NO982275L (no) 1998-07-29
AU698062B2 (en) 1998-10-22
PT863766E (pt) 2000-11-30
MX9803993A (es) 1998-09-30
US5641750A (en) 1997-06-24
JP2000502057A (ja) 2000-02-22
EP0863766B1 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
NO982275D0 (no) FremgangsmÕter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
NO982276D0 (no) FremgangsmÕte for behandling av retinal ganglioncelleskade under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
CA2232789A1 (en) Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product
ATE98219T1 (de) Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte.
IL121790A0 (en) Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor (GDNF) protein product
DE69023637D1 (de) Bakterien transformiert mit Expressionsplasmiden, die für den menschlichen NEUROTHROPHEN WIMPER FAKTOR (h-CNTF) kodieren, ihre Verwendung in der Herstellung von h-CNTF, Antikörper gegen h-CNTF und die Anwendung von h-CNTF in medizischer Behandlung.
JP2004262947A (ja) 網膜の色素沈着された上皮由来の神経栄養性因子
WO2001009327A3 (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
DE69903612D1 (de) Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten
BR9915803A (pt) Composição para o tratamento de neuropatia da retina ou cabeça de nervo ótico, e, processo para tratamento de neuropatia da retina ou cabeça de nervo ótico
ATE144139T1 (de) Verwendung von phenylethanolaminen zur herstellung von medikamenten gegen augenleiden
WO2000053760A3 (en) Method of preventing the death of retinal neurons and treating ocular diseases
HUP9802314A2 (hu) Zeaxantin tiszta 3R-3'R sztereoizomerje makuláris degeneráció emberben való kezelésére
SU1297845A1 (ru) Способ лечени миопии
JP2006516112A5 (no)
IT1265305B1 (it) Derivati metallorganici degli acidi s-acil-2-(s)-(2-pirrolidon-5-(s)- carbonilamido)-3-mercapto propionici con selenio, procedimento per la
TH55765B (th) โปรตีนที่มีความว่องไวในการเป็นตัวปรับบังคับในการสร้างเส้นเลือดใหม่